Salaspils, Latvia

Uldis R Apsalon

This inventor holds 1 USPTO granted patent. Top assignees: Institut Bioorganicheskoi Khimii Imeni M.m. Shemyakina Akademii Nauk Ssr, Institut Organicheskogo Sinteza Akademii Nauk Latviiskoi Ssr. Active years: 1988.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Uldis R Apsalon. Retrieved from https://idiyas.com/inventor/uldis-r-apsalon

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0

Average Co-Inventor Count = 13.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 1988

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Uldis R. Apsalon: Inventor in Biotechnology.

Introduction

Uldis R. Apsalon is an inventor associated with Salaspils, Latvia. His recorded patent concerns the production of human leukocyte interferon using bacteria.

Latest Patents

Apsalon is credited with one patent: “Human Leukocyte Interferon N and a Method of Producing Same in Bacterial [Cells].” The invention addresses a method for producing human leukocyte interferon N in bacteria. 1 patent.

Career Highlights

Apsalon’s listed institutional affiliations include the Institute of Organic Synthesis of the Academy of Sciences of the Latvian SSR and the M. M. Shemyakin Institute of Bioorganic Chemistry of the USSR Academy of Sciences. These affiliations connect his work with research institutions focused on organic synthesis and bioorganic chemistry.

Collaborations

His listed coworkers include Vladimir I. Iovlev and Arnis E. Duk.

Conclusion

Uldis R. Apsalon’s recorded contribution is a patent on bacterial production of human leukocyte interferon N, associated with research institutions in Latvia and the former Soviet Union.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…